期刊文献+

帕利哌酮与利培酮治疗精神分裂症的临床疗效比较及对社会功能的影响 被引量:3

Comparison of Clinical Efficacy of Paliperidone and Risperidone in the Treatment of Schizophrenia and Its Effect on Social Function
下载PDF
导出
摘要 目的分析精神分裂症患者应用帕利哌酮与利培酮治疗的效果。方法随机选择在本院接受治疗的精神分裂症患者30例参与研究,随机平均分成两组,对照组选择利培酮治疗,观察组选择帕利哌酮治疗,比较两组效果。结果观察组治疗总有效率为93.33%,高于对照组总有效率73.33%;观察组治疗后物质生活态度、社会功能、躯体功能、心理功能得分均高于对照组(P<0.05)。结论帕利哌酮治疗精神分裂症能够提高疗效,改善社会功能,提高患者生活质量。 Objective To analyze the clinical efficacy of paliperidone and risperidone in the treatment of schizophrenia. Methods 30 patients with schizophrenia received treatment in our hospital were randomly divided into two groups randomly. The control group was treated with risperidone, the observation group was treated with paliperidone, and the effect of the two groups was compared.Results The total effective rate of the observation group was 93.33%,which was higher than that of the control group, the total effective rate was 73.33%. After treatment, the scores of life attitude, social function, physical function and psychological function of the observation group were all higher than those of the control group (P〈0.05).Conclusion Paliperidone in treatment of schizophrenia can improve the curative effect, improve the social function, improve the quality of life of patients.
作者 陈永丽
出处 《中国继续医学教育》 2016年第29期157-158,共2页 China Continuing Medical Education
关键词 精神分裂症 帕利哌酮 利培酮 社会功能 Schizophrenia Paliperidone Risperidone Social function
  • 相关文献

参考文献8

二级参考文献83

  • 1黄文武,姜德国.抗精神病新药阿立哌唑[J].上海精神医学,2003,15(5):307-308. 被引量:153
  • 2刘俊彪,吴靖华.氯丙嗪、氯氮平、利培酮对首发精神分裂症患者糖代谢、血脂和体重的影响[J].中国神经精神疾病杂志,2004,30(4):293-295. 被引量:41
  • 3徐俊冕.精神分裂症药物治疗的新经验[J].上海精神医学,2004,16(2):124-125. 被引量:32
  • 4Chwieduk CM,Keating GM. Paliperidone extended release:areview of its use in the management of schizophrenia[ J]. 2010,70( 10) :1295-1317.
  • 5Canuso CM, Battisti WP. Paliperidone extended-release : areview of efficacy and tolerability in schizophrenia,schizoaffective disorder and bipolar mania [ J ]. ExpertOpin Pharmacother, 2010,11 ( 15 ) ;2557-2567.
  • 6Vermeir M, Naessens I,Remmerie B, et al. Absorption,metabolism ,and excretion cf paliperidone, a new monoamineiicantagonist,in humans [J]. Drug Metab Dispos,2008,36(4) :769-779.
  • 7Kramer M,Simpson G, Maciulis V,et al. One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia [ J ]. CNS5pecir,2010,15(8) :506-514.
  • 8Jones MP,Nicholl D,Trakas K. Efficacy and tolerability ofpaliperidone ER and other oral atypical antipsychotics inschizophrenia[ J ]. Int J Clin Pharmacol Ther9 2010, 48(6);383-399.
  • 9Canuso CM, Bossie CA, Turkoz I,et al. Paliperidoneextended-release for schizophrenia : effects on symptomsand functioning in acutely ill patients with negativesymptoms[ J].Schizophr Res,2009 ,113( 1 ) :56-64.
  • 10Marder SR,Kramer M,Ford L,et al. Efficacy and safety ofpaliperidone extended-release tablets:results of a 6-week,randomized,placebo-controlled study[ J]. Biol Psychiatry,2007,62(12) :1363-1370.

共引文献174

同被引文献20

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部